Skip to main content
Premium Trial:

Request an Annual Quote

BioCommerce Week s Index to the Diversified Molecular Biology Tools Companies: Sep 23, 2004

Invitrogen Advances 8 Percent on Index

Shares of Invitrogen closed up at $58.49 at market close on Tuesday, 9 percent over last week’s close, to lead gainers over the week on BioCommerce Week’s Index to the Diversified Biology Tools Companies. Overall, the index finished up for a third-straight week at $32.19 from $31.71 one week ago (see table).

The index is a weekly compliation of stock prices of molecular tools companies with multiple platform technologies or business units, executives dedicated to integrated biology efforts, or have made investments in the field. These companies may be the first to react to the demands of the emerging market developing to create a layer of interoperative technology that bridges the data silos of the ‘omics’ industries and provides a broader view of molecular biology processes.

Invitrogen’s rise comes after the company was added to the S&P MidCap 400 Index after the close of trading Monday. PerkinElmer led losers with a 3.6 percent fall, finishing at $18.30 from $18.71 last week.

— Mo Krochmal ([email protected])

File Attachments
The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.